A First for FSGS Patients: What the sparsentan Approval Means for You
During this live discussion, moderated by NephCure's COO Lauren Eva and CEO Josh Tarnoff, leading physicians Drs. Kirk Campbell, Laura Mariani, and Howard Trachtman walked through what this sparsentan FDA approval means for the FSGS community. They also discussed who may benefit and what patients and families should know as they navigate next steps.
▶︎
2025 update on what's happening in IgA Nephropathy
▶︎
NestJS Full Course for Beginners in 2026 | Build a Production-Ready API
▶︎
IgA nephropathy and pregnancy
▶︎
6.8.26 Board of Selectmen Meeting
▶︎
A First for FSGS Patients: What the sparsentan Approval Means for You
▶︎
Improve Your Kidney Function In 24 Hours (5 Easy Habits)
▶︎
Restoring More Than Hair: Addressing the Whole Patient with Alopecia Areata (AA) Webinar
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
Whats Next for IgAN
▶︎
DANGEROUS or Normal? What Your Dropping eGFR Really Means After 60
▶︎
Built for Impact: Lessons from the Super Clinics Leading the Way | 2025 USA Conference
▶︎
Understanding Your Kidney Bloodwork And When To See A Nephrologist With Dr Pandeya
▶︎
CNS Infections | Clinical Medicine
▶︎
The Shocking Reason Why Keir Starmer Has Resigned: Top Economist
▶︎
Andy Burnham delivers speech to set out economic vision – watch live
▶︎
The 3 foods you're eating daily that fuel cancer growth | Dr William Li
▶︎
Update on FDA Decision About Sparsentan for FSGS | NephCure Town Hall
▶︎
A New Era of PKD Treatments: MicroRNA Inhibitors
▶︎
A Comprehensive Guide to the New Standard of Care for Uveal Melanoma
▶︎